AACC 2013 Booth Presentation: What’s in a number? Can Quantitative Drug Testing Results Be Used to Delineate Partial vs. Full Dose Compliance


Dr. McMillin is a medical director of the Toxicology laboratories and co-medical director of Pharmacogenetics at ARUP, as well as an associate professor of pathology at the University of Utah School of Medicine. She received her PhD in pharmacology and toxicology from the University of Utah and is certified by the American Board of Clinical Chemistry in clinical chemistry and toxicological chemistry.

Originally presented on July 31, 2013, in Houston, Texas.

Lecture Presenter

Gwendolyn McMillin, PhD, DABCC(CC,TC)

Gwendolyn McMillin, PhD, DABCC(CC,TC)

Medical Director, Toxicology
ARUP Laboratories
Co-Medical Director, Pharmacogenetics
ARUP Laboratories
Associate Professor of Pathology
University of Utah School of Medicine

Urine drug testing is a useful tool for evaluating adherence to prescribed medication, particularly in pain management. For some drugs, such as opioids, quantitative results help define the patient phenotype and guide interpretation of adherence, but can be over-interpreted. This presentation will focus on using quantitative results to evaluate drug adherence vs. estimating adherence to a specific dose of a drug.

Sponsored by:

University of Utah School of Medicine, Department of Pathology, and ARUP Laboratories